Patients reaching treatment targets with once-weekly semaglutide in real-world practice: pooled analysis of four SURE studies

被引：0
|
作者：
Rudofsky, G. [1 ]
Bodholdt, U. [2 ]
Catarig, A. -M. [3 ]
Ekberg, N. Rajamand [4 ]
Erhan, U. [3 ]
Liutkus, J. F. [5 ]
Tariq, M. [6 ]
Holmes, P. [7 ]
机构：
[1] Kantonssp, Olten, Switzerland
[2] Kastrup Doctors, Copenhagen, Denmark
[3] Novo Nordisk AS, Soborg, Denmark
[4] Karolinska Inst, Stockholm, Sweden
[5] Joanne F Liutkus Med Profess Corp, Cambridge, ON, Canada
[6] Novo Nordisk Serv Ctr India Private Ltd, Bangalore, Karnataka, India
[7] St Georges Med Practice, Darlington, Durham, England
来源：
DIABETOLOGIA | 2021年 / 64卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
447
引用
收藏
页码：230 / 231
页数：2
相关论文
共 50 条
  • [1] Real-world use of once-weekly semaglutide in diverse patient populations with type 2 diabetes: pooled analysis of four SURE studies
    Yale, J. -F.
    Catarig, A. -M.
    Catrina, S. -B.
    Erhan, U.
    Sathyapalan, T.
    Schultes, B.
    Tariq, M.
    Knudsen, S. T.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 230 - 230
  • [2] Real-world use of once-weekly semaglutide in patients with type 2 diabetes: pooled analysis of data from four SURE studies by baseline characteristic subgroups
    Yale, Jean-Francois
    Bodholdt, Ulrik
    Catarig, Andrei-Mircea
    Catrina, Sergiu
    Clark, Alice
    Ekberg, Neda Rajamand
    Erhan, Umut
    Holmes, Patrick
    Knudsen, Soren Tang
    Liutkus, Joanne
    Sathyapalan, Thozhukat
    Schultes, Bernd
    Rudofsky, Gottfried
    BMJ OPEN DIABETES RESEARCH & CARE, 2022, 10 (02)
  • [3] Real-world safety profile of once-weekly semaglutide in people with type 2 diabetes: Analysis of pooled data from the SemaglUtide Real-world Evidence (SURE) programme
    Yale, Jean-Francois
    Major-Pedersen, Atheline
    Catarig, Andrei-Mircea
    Jain, Rashmi
    Menzen, Markus
    Holmes, Patrick
    DIABETES OBESITY & METABOLISM, 2024, 26 (10): : 4429 - 4440
  • [4] Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany
    Menzen, Markus
    Berentzen, Tina Landsvig
    Catarig, Andrei-Mircea
    Pieperhoff, Sebastian
    Simon, Joerg
    Jacob, Stephan
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2023, 131 (04) : 205 - 215
  • [5] Efficacy and Safety of Once-Weekly Semaglutide in People with Type 1 Diabetes in Real-World Practice
    Bellido, Virginia
    Herguido, Noelia Gros
    Amuedo, Sandra
    Ariza, Luis Baena
    Alfonso, Soto M.
    DIABETES, 2023, 72
  • [6] Real-world use of once-weekly semaglutide in type 2 diabetes: Results from the SURE UK study
    Holmes, P.
    Catarig, A. M.
    Clark, A.
    Erhan, U.
    Sathyapalan, T.
    DIABETIC MEDICINE, 2021, 38
  • [7] Once-weekly semaglutide use in patients with type 2 diabetes: Real-world data from the SURE Italy observational study
    Napoli, Raffaele
    Berra, Cesare
    Catarig, Andrei-Mircea
    Di Loreto, Chiara
    Donatiello, Emily
    Berentzen, Tina Landsvig
    Pitocco, Dario
    Giorgino, Francesco
    DIABETES OBESITY & METABOLISM, 2023, 25 (06): : 1658 - 1667
  • [8] Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study
    Wolffenbuttel, Bruce H. R.
    Brugts, Michel P.
    Catarig, Andrei-Mircea
    Clark, Alice
    Kok, Maarten
    Lieverse, Aloysius G.
    van Soest, Jaap
    ADVANCES IN THERAPY, 2023, 40 (03) : 920 - 933
  • [9] Once-Weekly Semaglutide Use in Type 2 Diabetes: Real-World Data from the SURE Netherlands Observational Study
    Bruce H. R. Wolffenbuttel
    Michel P. Brugts
    Andrei-Mircea Catarig
    Alice Clark
    Maarten Kok
    Aloysius G. Lieverse
    Jaap van Soest
    Advances in Therapy, 2023, 40 : 920 - 933
  • [10] Real-world use of once-weekly semaglutide in patients with type 2 diabetes at an outpatient clinic in Spain
    Garcia de Lucas, Maria Dolores
    Pablo Miramontes-Gonzalez, Jose
    Aviles-Bueno, Beatriz
    Isabel Jimenez-Millan, Ana
    Rivas-Ruiz, Francisco
    Perez-Belmonte, Luis M.
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
12345